argenx NV ADR - Asset Resilience Ratio

Latest as of June 2026: 15.95%

argenx NV ADR (ARGX) has an Asset Resilience Ratio of 15.95% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See argenx NV ADR current assets vs equity to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

$1.60 Billion

Cash + Short-term Investments

Total Assets

$10.03 Billion

All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio Trend (2012–2025)

This chart shows how argenx NV ADR's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see argenx NV ADR assets under control.

Liquid Assets Composition Over Time

This chart breaks down argenx NV ADR's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore argenx NV ADR (ARGX) investment intensity to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$1.60 Billion	15.95%
Total Liquid Assets	$1.60 Billion	15.95%

Asset Resilience Insights

Good Liquidity Position: argenx NV ADR maintains a healthy 15.95% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company has significant short-term investments, indicating active treasury management.

argenx NV ADR Industry Peers by Asset Resilience Ratio

Compare argenx NV ADR's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	Biotechnology	62.31%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Tubize-Fin BR:TUB	Biotechnology	2.50%
Aurinia Pharmaceuticals Inc NASDAQ:AUPH	Biotechnology	33.23%
Nanobiotix NASDAQ:NBTX	Biotechnology	4.71%
Innovita Biological Technology Co. Ltd. A SHG:688253	Biotechnology	65.12%
PYC Therapeutics Ltd AU:PYC	Biotechnology	83.51%

Annual Asset Resilience Ratio for argenx NV ADR (2012–2025)

The table below shows the annual Asset Resilience Ratio data for argenx NV ADR.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	10.93%	$948.75 Million	$8.68 Billion	-19.37pp
2024-12-31	30.29%	$1.88 Billion	$6.20 Billion	+5.39pp
2023-12-31	24.90%	$1.13 Billion	$4.54 Billion	-19.51pp
2022-12-31	44.41%	$1.39 Billion	$3.13 Billion	+9.25pp
2021-12-31	35.16%	$1.00 Billion	$2.85 Billion	+0.95pp
2020-12-31	34.20%	$779.65 Million	$2.28 Billion	-35.88pp
2019-12-31	70.08%	$1.13 Billion	$1.61 Billion	+21.07pp
2018-12-31	49.01%	$324.33 Million	$661.70 Million	+3.48pp
2017-12-31	45.54%	$202.64 Million	$444.98 Million	+39.08pp
2016-12-31	6.46%	$7.18 Million	$111.24 Million	-7.10pp
2015-12-31	13.56%	$6.81 Million	$50.25 Million	-35.89pp
2014-12-31	49.45%	$28.93 Million	$58.51 Million	+47.45pp
2013-12-31	2.00%	$690.44K	$34.54 Million	-4.06pp
2012-12-31	6.06%	$1.39 Million	$22.93 Million	--

pp = percentage points

About argenx NV ADR

NASDAQ:ARGX USA Biotechnology

Market Cap

$48.76 Billion

Market Cap Rank

#593 Global

#291 in USA

Share Price

$787.95

Change (1 day)

-0.66%

52-Week Range

$532.27 - $929.61

All Time High

$929.61